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Abstract Background: There is little information on the status of the implementation of
the isotretinoin Pregnancy Prevention Programme (PPP) in the EU, and on
compliance with this programme by the regulatory agencies.
Objective: The aim of the study was to obtain information on implementation
of the harmonized PPP of isotretinoin in the EU member states plus Norway
and Iceland.
Materials and Methods: In January 2009, a questionnaire (request for non-
urgent information [NUI]) was sent to all 25 EUmember states, plus Norway
and Iceland, to collect information on the implementation status of the PPP
and its effectiveness.
Results: The response rate was 82% (22 of the 27 countries). In 21 of the 27mem-
ber states, isotretinoin is marketed and the PPP is in force, and in 18 of the 22
responding countries, the total required elements (seven) following a formal EU
review are incorporated in the PPP. Seven member states had additional mea-
sures in place. In spite of implementation of the PPP and additional measures,
a total of 143 isotretinoin-exposed pregnancies have been reported in 16 of the
22 responding member states since implementation of the harmonized PPP.
Conclusions:Despite implementation of the isotretinoin PPP in most member
states, isotretinoin-exposed pregnancies were reported. This has led some
member states to implement additional measures to the PPP, resulting in
inconsistency with the approach agreed in 2003 following the European-wide
review. It has been further suggested that common elements should be devel-
oped for PPPs for all medicines that are known to carry a high teratogenic
risk.
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Background
Isotretinoin is a vitamin A derivative, licensed
in the EU for the treatment of severe acne that
has not responded to other treatments.[1] Like
all vitamin A derivatives, isotretinoin is highly
teratogenic; the rate of teratogenicity of vitamin
A derivatives is comparable to the rate of terato-
genicity of thalidomide.[2]
In 1982, isotretinoin was licensed in the US
and labelled a category Xmedication (agents that
have demonstrated clear risk of fetal abnormal-
ities and whose risks outweigh the benefits of use
during pregnancy[3]). The isotretinoin embryopathy
consists of craniofacial, cardiac, thymic, and CNS
defects, and occurs in an estimated 26% of exposed
patients.[2] Exposure of isotretinoin beyond the
critical period,[2] i.e. the first 10 weeks following
conception, which is associated with the above-
mentioned embryopathy, can cause developmental
delays and other CNS effects at even higher fre-
quencies of approximately 40%.[4,5]
Despite warnings to avoid use of isotretinoin in
pregnancy, the first cases of congenital anomalies
associated with isotretinoin use were published in
1983.[6] Isotretinoin has been licensed for use in the
EU since 1984, and a Pregnancy Prevention Pro-
gramme (PPP) for isotretinoin was implemented by
theMarketingAuthorizationHolder (MAH;Roche)
in 1988[7] to minimize the risk of embryopathy. The
isotretinoin PPP consisted of five elements:
 a guidance document for physicians;
 checklist for prescribing to female patients;
 patient information brochure;
 contraception brochure;
 patient informed consent form.
In 2003, generic formulations of isotretinoin
entered the market. Following a European-wide
review and a European Commission (EC) deci-
sion, an EU PPP was agreed that is applicable to
all MAHs for isotretinoin products.
Following the EC decision in 2003,[1] the PPP
was revised to contain the previous five elements,
as well as a guidance document for pharmacists
and more specific educational material for pa-
tients. The indication for use of isotretinoin was
also restricted to its second-line use in the treat-
ment of ‘‘severe forms of acne resistant to ade-
quate courses of standard therapy with systemic
antibacterial medication and topical therapy’’, in
contrast to its previous indication for the first-line
treatment of ‘‘severe cystic acne and acne con-
globata and acne resistant to other therapies’’.[8]
Despite implementation of the EU PPP, preg-
nancies have still been reported during isotreti-
noin use,[9,10] and this has led to several initiatives
to enhance the efficacy of the PPP in EU coun-
tries. Information on the status of implementa-
tion of the harmonized PPP in EUmember states,
plus Norway and Iceland, as well as other infor-
mation available might provide a basis for im-
proved risk minimization.
The aim of this study was therefore to evaluate
the status of current European-wide implementa-
tion of, and compliance with, the isotretinoin
PPP by the EU member states, plus Norway and
Iceland, by circulating a questionnaire, or non-
urgent information (NUI) request,[11] to the EU
member states plus Norway and Iceland.
Materials and Methods
On 26 January 2009, an NUI request was cir-
culated to the competent authorities of the 25 EU
member states plus Norway and Iceland, to col-
lect available information on the implementation
of, and compliance with, the isotretinoin PPP by
the EU member states plus Norway and Iceland.
Three weeks after sending the NUI, a reminder
was circulated. Last responses were received
7 weeks after the first mailing.
Circulating an NUI to the EU member states
is an established method for exchange of infor-
mation between national competent authorities
in the member states and the European Medi-
cines Agency on safety issues. The purpose of an
NUI is either to inform, or to obtain information,
for instance via questionnaire, from the other
member states on the status of a specific safety
issue. In the latter, a report compiled from the
responses can then be used for a discussion in the
Pharmacovigilance Working Party (PhVWP) of
the Committee for Medicinal Products for Human
Use of the EC on this specific safety issue.
This current NUI consisted of seven questions
(see table I). The responses were collected and
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discussed during a meeting of the PhVWP on 16
March 2009.
Descriptive statistics were used to analyze the
responses.
Results
Twenty-two of the 27 countries (82%) partici-
pating in the European regulatory network re-
sponded to the NUI request on implementation
of the isotretinoin PPP.
Isotretinoin is marketed in 21 of the 22 respond-
ingmember states (Swedenwas the only exception).
The original product of Roche (Roaccutane) was
licensed in 16 countries, of which 13 countries also
subsequently licensed one or more generic for-
mulations of isotretinoin. In Sweden, the product
is not licensed for use, but can be prescribed on
a named-patient basis. In five countries, only
generic formulations of isotretinoin are licensed,
and the majority of the licensed isotretinoin pro-
ducts were also marketed. The median number of
different isotretinoin products marketed per EU
member state (different dosages are pooled) is 4
(range 0–12).
The current EU PPP has seven elements, and
in 18 countries all seven elements are implement-
ed. Three countries did not effectuate the educa-
tional material for patients and, in addition, one
of these three countries did not have the contra-
ception brochure.
Seven countries had additional material as well
as the agreed European PPP materials. The ad-
ditional material consisted of a patient booklet
that patients presented at each prescriber and
pharmacist visit in order to follow-up and ensure
that all requested information (pregnancy test:
date and result, contraceptive status) was provided
before prescription, during prescription and dur-
ing dispensing, and a questionnaire or a preg-
nancy follow-up form. One of the other countries
with additional material had implemented an
additional measure that all women of child-
bearing age should have consulted a gynecologist
before starting treatment with oral isotretinoin.
Responses to the question on awareness of
isotretinoin-exposed pregnancies and eventual pre-
emptive measures were not answered consistently
and the results are therefore difficult to analyze.
One country reported an increase in pregnancies
in percentages (which have been published else-
where[9]), instead of the absolute number of preg-
nancies. The number of pregnancies was reported
over different time periods: either since launch, or
after implementation of the agreed EU PPP. Since
the marketing of isotretinoin in all responding
countries, the reported number of pregnancies
related to isotretinoin exposure was 393 in total
(range per country 0–289). Following implemen-
tation of the EU PPP (from 2003 to the beginning
of 2004), 143 pregnancies (range per country
0–65) related to isotretinoin exposure were re-
ported. Five countries reported zero pregnancies
and one country did not have data available. The
289 pregnancies reported in one country included
65 pregnancies following implementation of the
current PPP. Agencies have published informa-
tion on reported cases of isotretinoin-exposed
pregnancies in their national medical journal or
on their website, or instigated review by their
National Drug Safety Committee.
Table I. Questionnaire for evaluating implementation of the EU
isotretinoin Pregnancy Prevention Programme (PPP)[1] in the EU
member states circulated as a non-urgent information[11] request to
member states
1. Are isotretinoin medicinal products authorised and marketed in
your county? If yes, please specify.
2. Have you implemented a Pregnancy Prevention Programme
(PPP)a for isotretinoin? If yes, for which products?
3. Does the PPP(s) for isotretinoin contain the following materials:
I. Pharmacist’s Guide to dispensing isotretinoin
II. Physician’s Guide to prescribing isotretinoin
III. Checklist for prescribing to female patients
IV. Educational material for the male and/or female patients
V. Patient information brochure
VI. Brochure on contraception
VII. An acknowledgement form for female patients
4. Was there additional material? If yes, please specify.
5. Are you aware of any isotretinoin-exposed pregnancies in your
country? If yes, were any pre-emptive measures taken to prevent
more isotretinoin-exposed pregnancies.
6. Do you consider the national PPP satisfactory? If no, please
specify
7. Do you have other relevant information?
a Because of a European Commission decision in October 2003,[1]
the European member states should implement a defined PPP
for isotretinoin-containing products in their country.
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Overall, eight countries reported that they
were satisfied with the isotretinoin PPP, while
nine countries were not. Two countries expressed
doubt on the effectiveness of the PPP, another
two countries stated that research is ongoing and
that at that moment no opinion could be ex-
pressed, and one country abstained from an-
swering this question.
The last question, whether there was other in-
formation relevant to the implementation of, and
compliance with, the isotretinoin PPP elicited
information on additional activities undertaken
by each country. In two countries, Dear Health-
care Professional Communication (DHPC) let-
ters were sent reminding physicians about the
PPP and reminding pharmacists on dispensing
restrictions. In one country, a policy had been
implemented, restricting the prescription of iso-
tretinoin to dermatologists only. One country
was assessing the content of educational materials.
In another country, a cross-sectional study was
conducted in January 2008 to assess compliance
with PPP recommendations. The results of this
study[12] showed that healthcare professionals
were aware of the teratogenicity of isotretinoin,
but were not compliant with the recommend-
ations of the PPP, and that women of childbearing
potential were not informed of the risk of terato-
genicity associated with the use of isotretinoin
during pregnancy before initiating treatment.
It was also suggested by one of themember states
that harmonization of PPPs for different teratogenic
active substances (isotretinoin, thalidomide and le-
nalidomide) should be undertaken.
Discussion
All responding member states in which iso-
tretinoin is marketed have implemented a PPP.
The fact that five countries did not respond limits
the results of this investigation. Of the respond-
ing member states with a national PPP in force,
18 of 22 countries (82%) reported that the PPP
contained all seven elements agreed following the
European-wide review in 2003. Despite these mea-
sures, isotretinoin-exposed pregnancies continue
to occur in the responding countries; however,
details on these pregnancies are lacking.
Competent authorities hold different opinions
as to the effectiveness of the isotretinoin PPP, and
these opinions were not related in any way to the
actual number of pregnancies in that country.
Several member states are considering, or have
already implemented, additional measures to the
EU-agreed PPP on a national level.
A limitation of this investigation could be
measurement at only one point in time, i.e. at the
beginning of 2009. However, from information
provided by MAHs in their periodic safety up-
date reports, it is known that implementation
status is still valid. Moreover, it is possible that
socially favourable answers were given by some
countries to present their results in a more posi-
tive light.
As a post-authorization commitment follow-
ing the regulatory referral in 2003, the MAH of
the original product, Roaccutane (Roche), pro-
vided 6-monthly reports on the implementation
and effectiveness of ‘infoRM’, the risk minimi-
zation measures in place until 2010. Currently,
yearly reports are to be provided. These reports
provide cumulative data of pregnancies reported
to theMAH. Based on the well known limitations
of spontaneous reporting, there is probably a
degree of underreporting.[13] To have a complete
overview, female users of childbearing age would
need to be included in a register for complete
follow-up. In Sweden, where isotretinoin is pro-
vided on a named-patient basis, patients can be
closely monitored, and a total of 11 pregnancies
have been reported during, or just after stopping,
the use of isotretinoin.
The additional measures taken by some mem-
ber states add to the complexity of evaluation of
compliance with the PPP. Adding to the chal-
lenges faced is the fact that there are cases re-
ported in which pregnancy occurred after careful
compliance with the isotretinoin PPP.[14] An as-
sessment of the results of the US PPP concluded
that patient failure to use two contraceptive
methods was the most common reason for fetal
exposure.[15] Furthermore, a study in France[9]
showed that in 32% of isotretinoin-exposed preg-
nancies no contraceptive methods had been used.
From personal communication with prescribers
in the Netherlands, it is known that some patients
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are opposed to contraception, e.g. for religious
reasons. However, withholding isotretinoin is
regarded as undertreatment of these patients,
leaving ethical challenges.
Half of the responding member states con-
sidered the effectiveness of the PPP to be insuf-
ficient. This leads to the question of whether the
ultimate goal of a PPP should be zero exposed
pregnancies, zero infants with congenital mal-
formations or zero women who are uninformed
of the risks of pregnancy during isotretinoin treat-
ment. The incidence of congenital malformations
in the general population, i.e. 2–5% of all preg-
nancies,[16,17] should also be taken into account.
Furthermore, the influence of public and po-
litical opinion on healthcare challenges such as
this is substantial. The initiative in the US to in-
troduce the stricter PPP, iPledge, in 2006 seems to
have perpetuated the concept of zero risk of be-
coming pregnant during isotretinoin treatment,
by implying that all congenital malformations in
the isotretinoin user group are attributable to
isotretinoin exposure.
The greatest challenge in all PPPs is human
error, or varying levels of commitment to the use
of adequate contraceptive measures. The Pearl
index (measure of contraceptive failure) of var-
ious forms of contraception ranges from 0.1 to
2.5 per 100 women at 1 year.[18] In the US in 2001,
5% of women aged 15–44 years had an unin-
tended pregnancy.[19] Pregnancy rates during
isotretinoin use are lower (0.3%).[20]
To strengthen the European isotretinoin PPP,
a very strict programme such as iPledge, for in-
stance, could be initiated. Other measures might
increase the effectiveness of the isotretinoin PPP,
such as the use of hormonal implants for contra-
ception, or restricting prescription of isotretinoin
to dermatologists in specialized centres only. In
these centres, specially trained nurses could su-
pervise the provision of information to patients,
as well as checking pregnancy test results and other
tasks. Besides increasing compliance, monitoring
of the effectiveness of the PPP could be more
rigorously performed. In addition, greater uni-
formity of implementation of the PPP and of data
collection within the EU member states would
provide more robust results for evaluation of the
effectiveness of risk minimization measures. A
harmonized, amendedEUPPP should also be based
on realistic goals balancing maximum compliance
with a streamlined, realistic administrative work-
load for all involved parties.
Conclusions
Despite challenges in assessing the effective-
ness of the implementation of isotretinoin PPPs
in European member states, data gathered from
national competent authorities via a questionnaire
survey showed a low rate of occurrence of ex-
posed pregnancies but a significant level of con-
cern about the effectiveness of implementation of
the PPP. An amended harmonized isotretinoin
PPP should be considered that has a clearly stated
goal and maximum demonstrated effectiveness
with rigorous uniform monitoring. It has been
further suggested that common elements should
be developed for PPPs for all medicines that are
known to carry a high teratogenic risk.
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